# OnCo record ev-303 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ev-303/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ev-303", "NCT03924895" ;
  schema:name "EV-303 / KEYNOTE-905"@en ;
  schema:alternateName "EV-303"@en, "KEYNOTE-905"@en ;
  schema:description "For patients who cannot have cisplatin, the ADC-immunotherapy pair around surgery cut the risk of recurrence or death by 60% and the risk of death by half."@en ;
  schema:url <https://onco.cc/trials/ev-303/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03924895>, <https://www.cancernetwork.com/view/fda-oks-pembrolizumab-enfortumab-vedotin-in-muscle-invasive-bladder-cancer> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2019-07-24" ;
  onco:related <https://onco.cc/collections/src-cancer-network/> ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/nectin4/> ;
  onco:drugs <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/astellas/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> .